1. Autonomix Medical participated in a Virtual Investor CEO Connect segment. 2. CEO Brad Hauser emphasized IP protection and broader applications of technology. 3. The company's platform targets pain management beyond pancreatic cancer. 4. Technology is investigational and not yet cleared for U.S. marketing. 5. Autonomix aims to revolutionize nerve-targeted treatments with innovative devices.
FAQ
Why Bullish?
The CEO's focus on expanding technology applications indicates growth potential. Historical examples show companies gain market value with solid IP expansion plans.
How important is it?
The company's initiatives in pain management and technology expansion could significantly affect investor confidence and future valuations.
Why Long Term?
The company's innovation trajectory suggests sustainable growth over time, much like other medical advancements that took years to mature.
Access the segment here
THE WOODLANDS, TX, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ:AMIX) ("Autonomix" or the "Company"), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced it recently participated in a Virtual Investor CEO Connect segment.
As part of the segment, Brad Hauser, CEO of Autonomix, outlined two key priorities shaping the Company's trajectory: strengthening its platform through intellectual property protection and evaluating opportunities beyond pancreatic cancer, including potential applications in cardiovascular, pulmonary and interventional pain management areas.
The Virtual Investor CEO Connect segment is now available here.
About Autonomix Medical, Inc.
Autonomix is a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system are diagnosed and treated. The Company's first-in-class platform system technology includes a catheter-based microchip sensing array that may have the ability to detect and differentiate neural signals with greater sensitivity than currently available technologies. We believe this will enable, for the first time ever, transvascular diagnosis and treatment of diseases involving the peripheral nervous system virtually anywhere in the body.
We are initially developing this technology for the treatment of pain, with initial trials focused on pancreatic cancer, a condition that causes debilitating pain and is without a reliable solution. Our technology constitutes a platform to address dozens of potential indications, including cardiology, hypertension and chronic pain management, across a wide disease spectrum. Our technology is investigational and has not yet been cleared for marketing in the United States.
For more information, visit autonomix.com and connect with the Company on X, LinkedIn, Instagram and Facebook.
Investor and Media Contact
JTC Team, LLC
Jenene Thomas
908.824.0775
autonomix@jtcir.com
